A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4656-4656
Author(s):  
W. K. Oh ◽  
E. Hagmann ◽  
J. Manola ◽  
D. J. George ◽  
T. D. Gilligan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase I ◽  
Phase I Study ◽  
Hormone Refractory Prostate Cancer ◽  
Weekly Docetaxel ◽  
Hormone Refractory

A phase I study of silibinin in hormone refractory prostate cancer

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4698-4698 ◽  
Author(s):  
T. Flaig ◽  
R. Agarwal ◽  
L.-J. Su ◽  
G. S. Harrison ◽  
D. L. Gustafson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase I ◽  
Phase I Study ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

scholarly journals A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer

Cancer ◽  
1995 ◽  
Vol 75 (8) ◽  
pp. 2159-2164 ◽  
Author(s):  
William D. Figg ◽  
Alain Thibault ◽  
Michael R. Cooper ◽  
Robert Reid ◽  
Donna Headlee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase I ◽  
Phase I Study ◽  
Somatostatin Analogue ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

scholarly journals Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients

2011 ◽  
Vol 105 (11) ◽  
pp. 1640-1645 ◽  
Author(s):  
G Bousquet ◽  
J Alexandre ◽  
C Le Tourneau ◽  
F Goldwasser ◽  
S Faivre ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase I ◽  
Cancer Patients ◽  
Phase I Study ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory ◽  
Bibf 1120
Sign in / Sign up

Export Citation Format

Share Document